FDA moves to remove boxed warnings from menopause hormone therapy
HHS and the FDA announced they will remove boxed warnings about cardiovascular disease, breast cancer and probable dementia from more than 20 menopausal hormone therapy products, while keeping the warning about endometrial cancer for systemic estrogen used alone.
EVIDENCE:
Regulatory action
WHY IT MATTERS
The original warnings were driven largely by the Women’s Health Initiative, whose participants averaged 63 years old and used older formulations. The change lets women and clinicians weigh benefits and risks by age, timing and route instead of starting from fear.
The FDA said updated labels will also recommend starting systemic hormone therapy before age 60 or within 10 years of menopause onset, when the balance of benefit and risk is most favorable. The decision followed an FDA expert panel on menopause and hormone therapy held in July 2025.
Contraindications have not changed. A history of breast or endometrial cancer, blood clots, stroke, heart disease, unexplained bleeding or active liver disease still calls for careful specialist review, and women with a uterus still need a progestogen alongside systemic estrogen.
Not everyone agreed. Consumer advocacy groups including Public Citizen and the National Center for Health Research argued the evidence did not justify removing the warnings. We will update this page as final label language is published.
PRIMARY SOURCE
U.S. Department of Health and Human Services and FDA announcement, November 10, 2025
FDA labeling change · menopausal hormone therapy
Educational summary reviewed by Farhan Tahir, MD. Not individual medical advice. Medicines named here require a prescription and medical supervision.
MORE FROM THE RESEARCH DESK
Keep reading.
Regulatory
·
FDA moves to remove boxed warnings from menopause hormone therapy
HHS and the FDA announced they will remove boxed warnings about cardiovascular disease, breast cancer and probable dementia from more than 20 menopausal hormone therapy products, while keeping the warning about endometrial cancer for systemic estrogen used alone.
Regulatory action
Approvals
·
FDA approves elinzanetant (Lynkuet), a dual NK1/NK3 blocker for hot flashes
The FDA approved Bayer’s elinzanetant, a once-nightly non-hormonal capsule for moderate to severe hot flashes and night sweats caused by menopause.
Phase 3 RCTs
Clinical Trials
·
TRAVERSE: testosterone does not raise major cardiac events in men with hypogonadism
In 5,246 men aged 45 to 80 with low testosterone and existing or high risk of cardiovascular disease, testosterone gel was noninferior to placebo for heart attack, stroke and cardiovascular death.
Human RCT